Synthetic peptide vaccines
- 12 November 2010
- journal article
- Published by Pleiades Publishing Ltd in Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry
- Vol. 4 (4) , 321-332
- https://doi.org/10.1134/s1990750810040025
Abstract
The review considers the stages of the development of synthetic peptide vaccines against infectious agents, novel approaches and technologies employed in this process, including bioinformatics, genomics, proteomics, large-scale peptide synthesis, high-throughput screening methods, the use of transgenic animals for modeling of human infections. An important role for the development and selection of efficient adjuvants for peptide immunogens is noted. The review contains examples of the developments of synthetic peptide vaccines against three infectious diseases (malaria, hepatitis C, and foot-and-mouth disease).Keywords
This publication has 90 references indexed in Scilit:
- A Burkholderia pseudomallei protein microarray reveals serodiagnostic and cross-reactive antigensProceedings of the National Academy of Sciences, 2009
- Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming ‘vaccine resistant malaria’Parasite Immunology, 2009
- Proteomics-Based Identification of Anchorless Cell Wall Proteins as Vaccine Candidates againstStaphylococcus aureusInfection and Immunity, 2009
- T-Cell Epitope Prediction: Rescaling Can Mask Biological Variation between MHC MoleculesPLoS Computational Biology, 2009
- Evaluation of MHC-II peptide binding prediction servers: applications for vaccine researchBMC Bioinformatics, 2008
- Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodiesThe Journal of Experimental Medicine, 2007
- Reconstruction of a pathway of antigen processing and class II MHC peptide captureThe EMBO Journal, 2007
- Novel Robust Hepatitis C Virus Mouse Efficacy ModelAntimicrobial Agents and Chemotherapy, 2006
- Treating viral hepatitis C: efficacy, side effects, and complicationsGut, 2006
- Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cellsEuropean Journal of Immunology, 1989